如果软件能够像现在的药物一样拯救生命，那么大数据就有望像大型制药公司那样发挥作用。
If software promises to save lives on the scale that drugs now can, big data may be expected to behave as a big pharma has done.
如果软件在拯救生命方面可望达到药物的水平，那么大数据也可能会和大型制药公司一样行事。
If software promises to save lives on the scale that drugs now can, big data may be expected to behave as big pharma has done.
这可能会导致更多的大型制药公司间并购。
要经营大型制药公司，目前看来不是好时候。
NOW is not a good time, it seems, to be running a big pharmaceuticals firm.
如此说来大型制药公司应当怎样做呢？
大型制药公司继续进军新兴市场。
然而大型制药公司的前景却已黯淡。
大型制药公司会说那没什么大不了，但我不同意。
很明显，大型制药公司已经得到这个讯息。
从某方面看，药品研发危机并不全是大型制药公司的责任。
In one sense, the research crunch is not entirely Big Pharma's fault.
抗癌药物曾一度不被诸如辉瑞制药等的大型制药公司看好。
Cancer was once unattractive for big pharmaceutical companies like Pfizer.
靠传统方法，大型制药公司无法及时推出新药以填补空缺的产品线。
With its traditional approach, Big Pharma is not coming up with new drugs fast enough to fill its emptying pipeline.
这会给大型制药公司和现有生物仿制药公司创造更多不同方式的合作机会。
This will create more and different partnering opportunities as both Big Pharma and established biosimilars players create pipelines of compounds.
“如果你跟大型制药公司的人这么说，他们可能会说你疯了，”Seder说。
"If you talk to people in a large pharmaceutical company about it, they would say you are nuts," Seder says.
把重点放在市场的利基新物就说明了一个潜在的战略，即可以追求大型制药公司。
A focus on the market for niche blockbuster drugs represents a potential strategy that can be pursued by large pharmaceutical companies.
但身为英国大型制药公司阿斯利康的首席执行官，满怀自信的他表明了制药业的远期前景。
But as chief executive of AstraZeneca, a big British drugs firm, his brimming self-confidence is a reminder of the genuine long-term promise of the pharmaceuticals industry.
私人腰包是研究项目不可或缺的资源并且许多正处于三期临床试验的新抗癌药由大型制药公司研发。
The private purse is an important source for good research and many of the new targeted cancer agents were developed in phase 3 trials by the big pharmaceutical companies.
阿斯利康（一家英国的大型制药公司）最近宣布作为削减成本的手段之一，它开始将生产转移到亚洲。
AstraZeneca, a big British drugs firm, recently announced that it will start shifting manufacturing operations to Asia as part of a cost-cuttingdrive.
与其他行业的公司不同，大型制药公司仍然将从研发到生产销售的大部分业务在公司内完成。
Unlike firms in other businesses, Big Pharma still does most things in-house, from research to manufacturing, sales and distribution.
但一些开辟这项技术的公司并未放弃，同时有越来越多的大型制药公司也开始涉足该领域。
But companies pioneering the technology have not given up and a growing number of large pharmaceutical companies are also starting to dip their toes in the water.
根据从大型制药公司获得的线报，联邦官员设计了一个计谋以阻止他对美国做同样的事情。
Faulconer, a customs official. Acting on tips from large drug companies, federal officials devised a plan to stop him from doing the same in the United States.
这个被允诺的优惠政策用于支持小型的学名药制药公司，但是大型制药公司发现了其中的一个漏洞。
This promised pot of gold was designed to support small generics firms—but Big Pharma has found a loophole.
这为大型制药公司的研究实验室如何陷入麻烦提供了解释：从传统化学转向新兴科学——生物技术。
This points to one explanation for how Big Pharma's research laboratories got into trouble: the shift from conventional chemistry to the "new science" of biotechnology.
像一些引进仿制药的大型制药公司，以及设备公司已经有很长一段时间没有对现有的产品做出改进。
Like Big Pharma, which introduced many "me too" drugs, device companies have sustained themselves by making small improvements to existing products.
原因之一可能是一些大型制药公司认为和解是买通仿制药品公司使之延迟推出降价药品时间的手段。
One reason could be that some drugs giants regard settlements as a way to bribe a generics firm to delay its introduction of a cut-price product.
朗曼认为，大型制药公司必须寻求分散经营，把精力集中在小部分核心领域内，比如药物的发现，研究，市场运作。
Mr Longman insists that big drugs firms must move towards a “disaggregated” model to focus on a few core areas of competence, such as drug discovery, development or marketing.
大型制药公司在高成本、高风险的新药开发过程中展开合作渐成趋势，兵团作战或许比单打独斗更具威力。
Large pharmaceutical companies in the high-cost, high-risk drug development process become the trend of cooperation, the Corps operations on their own may be more powerful than that.
但你可以看到，制药公司的研发投入往往比科技公司更多，谷歌公司在这方面的支出只及大型制药公司的一半。
But you can see that drug companies tend to spend more than those in the tech sector. Google spends half as much as a big pharmaceutical firm.
但你可以看到，制药公司的研发投入往往比科技公司更多，谷歌公司在这方面的支出只及大型制药公司的一半。
But you can see that drug companies tend to spend more than those in the tech sector. Google spends half as much as a big pharmaceutical firm.
应用推荐